ANKRD33 Inhibitors
ANKRD33 inhibitors encompass a diverse group of chemical compounds that act on various signaling pathways, indirectly leading to the inhibition of ANKRD33. These inhibitors operate by disrupting specific cellular processes that are essential for ANKRD33's functional activity. The mechanism of inhibition for each compound is rooted in the interruption of the signaling cascade at different junctures. For instance, compounds like staurosporine and imatinib target the ATP-binding sites of kinases that are potentially responsible for the activation or regulation of ANKRD33 through phosphorylation events.
The inhibition of these kinases prevents the necessary phosphorylation that ANKRD33 may require for its activity. Similarly, inhibitors like LY294002 and wortmannin disrupt the PI3K/Akt pathway, which could be crucial for the activation state or functional output of ANKRD33. Through these targeted actions, each inhibitor can help elucidate the role of ANKRD33 within various cellular contexts and its relationship with different signaling pathways. Understanding how ANKRD33 interacts with these pathways can provide insights into its biological functions and applications or implications in disease states.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It acts by binding to the ATP binding sites of these enzymes, effectively blocking their catalytic activity. ANKRD33 is dependent on phosphorylation for its function; thus, staurosporine can reduce ANKRD33 activity by inhibiting the kinase responsible for its phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of phosphatidylinositol 3-kinase (PI3K). PI3K signaling is crucial for many cellular processes, including metabolism and cell survival. Inhibition of PI3K can lead to a decrease in AKT phosphorylation, which is necessary for the proper functioning of a range of proteins. If ANKRD33's activity is AKT-dependent, LY294002 may decrease ANKRD33 activity indirectly via this mechanism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of MEK, which is part of the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation. Inhibition of MEK by PD98059 can lead to reduced ERK activation and thus might impede the phosphorylation status of proteins downstream or associated with ERK, which could include ANKRD33 if it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic Target of Rapamycin), which is a central protein in a signaling pathway important for cell growth and proliferation. If ANKRD33 is involved in processes downstream of mTOR, its functional activity could be diminished as a result of mTOR inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase, which is involved in the response to stress and inflammation. If ANKRD33 has a role in the p38 MAPK pathway, inhibition by SB203580 could reduce ANKRD33 activity by decreasing pathway signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another inhibitor of PI3K, like LY294002. It irreversibly inhibits PI3K by covalently binding to the enzyme, leading to downstream effects on AKT signaling. This could reduce the activity of proteins regulated by the AKT pathway, potentially including ANKRD33. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in controlling a number of cellular processes, including cell growth and apoptosis. If ANKRD33 is modulated by JNK signaling, SP600125 could lead to decreased ANKRD33 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases are involved in various signaling pathways that regulate cell proliferation, differentiation, and survival. If ANKRD33 is activated or modulated by Src kinases, PP2 could indirectly inhibit ANKRD33 activity by blocking these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It blocks the degradation of ubiquitinated proteins, potentially leading to an accumulation of regulatory proteins that can inhibit the function of other proteins. If ANKRD33 is negatively regulated by proteins that are normally degraded by the proteasome, bortezomib can lead to ANKRD33 inhibition. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gsα-subunit of heterotrimeric G proteins. If ANKRD33 activity is enhanced by signaling pathways involving Gsα, inhibition by NF449 could result in decreased ANKRD33 activity. | ||||||